admin – Page 2745 – Get News Story

Recurrent Glioblastoma Pipeline Appears Promising With 50+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Recurrent Glioblastoma Research. Learn more about our innovative pipeline today! @ Recurrent Glioblastoma Pipeline Outlook

Key Takeaways from the Recurrent Glioblastoma Pipeline Report

In July 2025, CarThera announced a study is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the tumour is seated.
DelveInsight’s Recurrent Glioblastoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Recurrent Glioblastoma treatment.
The leading Recurrent Glioblastoma Companies such as Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
Promising Recurrent Glioblastoma Pipeline Therapies such as Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.

Stay informed about the cutting-edge advancements in Recurrent Glioblastoma treatments. Download for updates and be a part of the revolution in care @ Recurrent Glioblastoma Clinical Trials Assessment

Recurrent Glioblastoma Emerging Drugs Profile

ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%.

GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.

Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.

VXM01: VAXIMM AG

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

The Recurrent Glioblastoma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent Glioblastoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent Glioblastoma Treatment.
Recurrent Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Recurrent Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent Glioblastoma Market

Stay informed about the Recurrent Glioblastoma Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Recurrent Glioblastoma Unmet Needs

Recurrent Glioblastoma Companies

Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.

Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Recurrent Glioblastoma Products have been categorized under various Molecule types such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Transform your understanding of the Recurrent Glioblastoma Pipeline! See the latest progress in drug development and clinical research @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspectives

Scope of the Recurrent Glioblastoma Pipeline Report

Coverage- Global
Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
Recurrent Glioblastoma Pipeline Therapies- Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.
Recurrent Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Recurrent Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Recurrent Glioblastoma Pipeline Analysis Today! @ Recurrent Glioblastoma Drugs and Companies

Table of Contents

Introduction
Executive Summary
Recurrent Glioblastoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ASC40: Ascletis
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
GX-I7: Genexine
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
VXM01: VAXIMM AG
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Recurrent Glioblastoma Key Companies
Recurrent Glioblastoma Key Products
Recurrent Glioblastoma- Unmet Needs
Recurrent Glioblastoma- Market Drivers and Barriers
Recurrent Glioblastoma- Future Perspectives and Conclusion
Recurrent Glioblastoma Analyst Views
Recurrent Glioblastoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/recurrent-glioblastoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Glioblastoma Pipeline Appears Promising With 50+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

B-Cell Non-Hodgkin Lymphoma Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight’s “B-Cell Non-Hodgkin Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive B-cell non-Hodgkin Lymphoma pipeline products in this space.

Explore our latest breakthroughs in B-Cell Non-Hodgkin Lymphoma Research. Learn more about our innovative pipeline today! @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook

Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report

In July 2025, Hoffmann-La Roche announced a Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients.
In July 2025, Novartis Pharmaceuticals announced a phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
In July 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as ‘refractory’) or has returned (also known as ‘relapsed’). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.
In July 2025, Incyte Biosciences Japan GK organized a study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.
DelveInsight’s B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
Promising B-Cell Non-Hodgkin Lymphoma Therapies such as Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.

Discover how the B-Cell Non-Hodgkin Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth B-Cell Non-Hodgkin Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ B-Cell Non-Hodgkin Lymphoma Clinical Trials and Studies

B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile

Valemetostat: Daiichi Sankyo

Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.

MB-106: Mustang Bio

MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.

CB-010: Caribou Biosciences

CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.

LP-284: Lantern Pharma

LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern’s RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.

The B-Cell Non-Hodgkin Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma Treatment.
B-Cell Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.

Get a detailed analysis of the latest innovations in the B-Cell Non-Hodgkin Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ B-Cell Non-Hodgkin Lymphoma Unmet Needs

B-Cell Non-Hodgkin Lymphoma Companies

Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.

B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming B-Cell Non-Hodgkin Lymphoma Therapies and key B-Cell Non-Hodgkin Lymphoma Developments @ B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report

Coverage- Global
B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
Promising B-Cell Non-Hodgkin Lymphoma Therapies– Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.
B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in B-Cell Non-Hodgkin Lymphoma drug development? Find out in DelveInsight’s exclusive B-Cell Non-Hodgkin Lymphoma Pipeline Report—access it now! @ B-Cell Non-Hodgkin Lymphoma Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
B-Cell Non-Hodgkin Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
B-Cell Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Valemetostat: Daiichi Sankyo
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CB-010: Caribou Biosciences
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
B-Cell Non-Hodgkin Lymphoma Key Companies
B-Cell Non-Hodgkin Lymphoma Key Products
B-Cell Non-Hodgkin Lymphoma- Unmet Needs
B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
B-Cell Non-Hodgkin Lymphoma Analyst Views
B-Cell Non-Hodgkin Lymphoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Non-Hodgkin Lymphoma Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

IBN Technologies Boosts Residential Civil Engineering Services

“IBN Technologies [USA]”

IBN Technologies introduces residential civil engineering services designed to help developers and construction firms streamline site design, manage grading and utility plans, and reduce internal design workload. With certified processes and digital tools, the company delivers compliant, cost-effective solutions tailored for modern residential projects across global markets.

Miami, Florida, 17 July 2025 In response to the accelerating demand for housing and urban infrastructure, IBN Technologies has expanded its portfolio of residential civil engineering services. This strategic move is designed to help developers, contractors, and architecture firms manage increasing project volumes while maintaining high technical standards and faster turnaround times.

The global housing market is under pressure due to population growth, land-use constraints, and evolving regulatory requirements. Civil engineering plays a pivotal role in addressing these challenges, especially in the residential sector. IBN Technologies delivers tailored, cost-effective services that assist firms in meeting their development goals on time and within budget.

IBN Technologies residential civil engineering services are built around flexibility, compliance, and digital integration. From grading and drainage design to construction documentation and permitting packages, the company provides technical support that scales with client needs and ensures quality at every stage of the project.

Ensure efficient delivery of civil engineering projects

Get a Free Consultation: https://www.ibntech.com/free-consultation-for-construction/

Industry Challenges in Residential Civil Engineering

The residential construction sector faces persistent operational and regulatory hurdles that slow project delivery and strain in-house teams:

Lack of skilled civil engineers to handle complex site development

Delays in permits and approvals due to incomplete or inconsistent drawings

Rising costs associated with internal design and drafting resources

Coordination issues across multidisciplinary teams and external consultants

Limited adoption of digital tools for collaboration and project tracking

IBN Technologies’ Residential Civil Engineering Solutions

IBN Technologies addresses these challenges through a robust, outsourced service model that offers scalable residential civil engineering solutions. The company’s approach integrates technical expertise, digital tools, and global delivery to support the full lifecycle of residential site development.

Key services include:

✅ Manages RFI workflows, design updates, and technical communication

✅ Assembles final as-built documents, warranty data, and complete handover packages

✅ Produces accurate quantity estimates and cost analyses for project bids

✅ Prepares build-ready documentation aligned with specific project guidelines

✅ Assists with final-stage documentation and seamless handover execution

✅ Plans material requirements and drafts cost schedules for budget planning

✅ Establishes systematic budget monitoring for effective expense control

✅ Enables remote oversight of key milestones, progress reports, and delivery timelines

IBN Technologies employs a team of qualified engineers and drafters with deep experience in U.S., UK, and APAC code requirements. Projects are managed through cloud-based collaboration platforms, allowing clients to review, annotate, and approve drawings in real time. All deliverables go through a multi-level QA process to ensure accuracy, compliance, and consistency.

Key Benefits of Outsourcing Civil Engineering Services

Outsourcing residential civil engineering to IBN Technologies offers construction and development firms a strategic advantage:

Reduced operational costs with savings over in-house teams

Accelerated project timelines through efficient workflows and expert staffing

Flexible resource allocation to match project scale and complexity

Access to global expertise without recruitment delays

Improved design accuracy through advanced digital drafting and QA systems

IBN Technologies Elevates Standards in Civil Engineering Outsourcing

As the need for specialized engineering expertise continues to grow, IBN Technologies has set a new standard in the outsourcing industry through its structured and performance-driven model:

✅ Up to 70% in cost reduction achieved while maintaining exceptional service quality

✅ ISO 9001:2015 | 20000:2018 | 27001:2022 certifications validate strong data security and regulatory compliance

✅ More than 26 years of successful project execution in global civil engineering sectors

✅ Digitally integrated workflows ensure real-time project tracking and remote collaboration

Unlike traditional in-house teams and typical outsourcing providers, IBN Technologies delivers Civil Engineering Outsourcing Services focused on technical accuracy, scalable resources, and seamless digital integration. This approach enables on-time delivery, optimized project costs, and high-quality performance across a wide range of development scopes.

Scale your engineering capacity without adding internal load

Contact Now: https://www.ibntech.com/contact-us/

Future-Focused Engineering Support for a Growing Sector

As cities expand and residential needs evolve, engineering teams must find smarter ways to deliver high-quality outcomes under tighter timelines. IBN Technologies is uniquely positioned to support this shift with its integrated civil engineering services designed for the realities of modern development.

The firm’s outsourced residential civil engineering solutions enable companies to stay ahead of market demands without sacrificing quality or compliance. By offloading time-intensive technical tasks, clients gain the bandwidth to focus on project execution, stakeholder management, and growth strategies.

IBN Technologies’ forward-thinking approach—combining certified processes, digital workflows, and experienced professionals—ensures every client receives consistent, high-value support. The company continues to invest in new technologies, talent development, and process improvement to remain a trusted partner in civil engineering outsourcing.

About IBN Technologies                       

IBN Technologies LLC, an outsourcing specialist with 26 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in the use- Real estate and construction (civil engineering) Industry, RPA, Intelligent Process Automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO, Outsourcing services in finance and accounting, including CPAs, Hedge funds, alternative investments, banking, travel, and human resources. It offers customized solutions that drive AR efficiency and growth.                 

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IBN Technologies Boosts Residential Civil Engineering Services

Online Payroll Services by IBN Technologies Simplify HR Operations

“Online Payroll Services [USA]”

IBN Technologies online payroll services designed to simplify wage processing, ensure compliance, and support hybrid and global teams. They offer end-to-end solution, secure data handling, and real-time payroll execution tailored to industry-specific needs—helping businesses reduce costs, avoid errors, and scale operations effectively.

Miami, Florida, 17 July 2025 In response to rising payroll complexity and expanding global workforce demands, IBN Technologies has introduced a comprehensive suite of online payroll services tailored to organizations of all sizes. Built for adaptability and regulatory alignment, the new platform addresses modern business needs by enabling end-to-end payroll processing.

As hybrid and remote employment models gain traction and tax laws fluctuate in various jurisdictions, companies face mounting pressure to upgrade outdated payroll methods. IBN Technologies’ online payroll solutions deliver a unified approach that removes inefficiencies, minimizes errors, and simplifies compliance across regions.

Backed by over 26 years of experience in finance and accounting outsourcing, IBN Technologies’ solution integrates smoothly into existing systems. Covering everything from tax submissions to real-time insights and encrypted data handling, the offering enables businesses to prioritize strategic advancement while ensuring every payroll cycle is accurate, timely, and ready for audit.

Need Reliable Payroll Solutions for Your U.S. Business?

Get a Free Consultation: https://www.ibntech.com/free-consultation-for-payroll-service/

Common Payroll Challenges Affecting Business Performance

Despite advancements in HR software, organizations still face recurring obstacles in managing payroll that affect internal performance:

Manual data input raises the likelihood of mistakes and payment delays

Tax legislation updates at federal, state, and local levels cause ongoing compliance issues

Older systems struggle to adapt to blended and dispersed workforce models

Inadequate security increases exposure to sensitive data breaches

HR and finance personnel spend excessive hours on repetitive administrative tasks

That’s why it’s crucial to have trusted payroll professionals like ours.

IBN Technologies’ Online Payroll Solutions: Precise, Adaptable, and Secure

IBN Technologies delivers a trusted payroll ecosystem that simplifies intricate payroll tasks. Every partnership begins with a thorough assessment of existing processes, workforce structure, and regulatory demands—allowing a personalized implementation of IBN Technologies’ online payroll services aligned to specific organizational goals.

Notable platform capabilities include:

✅ Customized payroll planning in accordance with manufacturing wage systems

✅ Full-spectrum tax handling and legal conformity for industrial sectors

✅ Monitoring of time-based compensation through real-time attendance tools

✅ Scheduled issuance of wages, bonuses, and overtime

✅ HR coordination for contract employees and variable shift rosters

✅ Centralized payroll logs with easy-to-access audit pathways

✅ Compensation analytics and reporting for union-compliant workplaces

✅ Guidance on cross-state employment rules and legal protocols

✅ Partnership with finance teams for accurate labor forecasting

✅ Encrypted processing of payroll information to maintain confidentiality

From logistics and healthcare to retail and manufacturing, IBN Technologies’ design and multilingual functionality offer a modern payroll approach ready to evolve with changing workforce demands.

Meaningful Results Through Specialized Payroll Delivery in the U.S.

As compensation frameworks change within American industries, more companies are turning to experienced payroll professionals to streamline operations. With increasing expectations around precision, regulatory readiness, and employee engagement, delegating payroll responsibilities has become an essential tactic for building consistency and reducing operational strain.

Accurate payroll execution and on-schedule payments help strengthen legal adherence, enhance productivity, and reinforce workforce confidence

Businesses have reported annual savings up to $59,000 through collaborations with expert providers like IBN Technologies—lowering administrative burden and reducing costly payroll miscalculations

Given the complexity of today’s labor compliance landscape, professional payroll support has become a fundamental need. IBN Technologies’ skilled team partners closely with each client to minimize disruptions, preserve payroll integrity, and manage cycles with zero margin for error. Each engagement is adapted to organizational frameworks, enabling stability and long-term scalability.

A prime example features a national logistics firm handling a geographically dispersed staff on a weekly pay frequency. IBN Technologies rolled out a tailored system that enhanced timesheet precision, streamlined tax compliance, and facilitated direct deposit scheduling at multiple branches. The result: improved financial oversight and stronger employee trust built on punctual payments and transparent deductions.

This success reflects how IBN Technologies’ secure, cloud-ready foundation—paired with local legal understanding—helps businesses reclaim time, reduce regulatory exposure, and build a resilient payroll structure.

Business Advantages of Partnering with IBN Technologies for Payroll

Engaging IBN Technologies to manage payroll services brings measurable improvements in operational outcomes:

Cost Efficiency: Achieve up to 70% savings over in-house payroll teams

Regulatory Readiness: Stay aligned with labor mandates and tax codes

Process Acceleration: Reduce manual effort through intelligent automation

Information Security: Protect data through high-grade encryption

Operational Flexibility: Scale services according to team size or structure changes

Future-Focused Payroll Solutions Backed by Proven Experience

As workforce strategies become more multifaceted and tax environments grow more demanding, organizations require payroll systems that adapt in real time. IBN Technologies provides the flexibility modern enterprises need through online payroll services that are customizable, dependable, and security-enhanced.

IBN Technologies’ online payroll solutions guide companies away from inefficient legacy tools toward streamlined, audit-ready systems that promote compliance, morale, and control.

With 24/7 multilingual support, transparent subscription-based pricing, and seamless integration with current systems, IBN Technologies continues to serve organizations seeking scalable payroll frameworks that evolve as their business grows.

Whether managing 50 employees or 5,000, IBN Technologies equips businesses to handle every payroll cycle with accuracy, confidence, and strategic focus.

Related Service:    

1. AP and AR Automation Services: https://www.ibntech.com/ap-ar-automation/    

2. Intelligent Process Automation: https://www.ibntech.com/intelligent-process-automation/       

About IBN Technologies                

IBN Technologies LLC, an outsourcing specialist with 26 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.                

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Online Payroll Services by IBN Technologies Simplify HR Operations

Copper Tubes Market Share, Comprehensive Analysis, Opportunity Assessment, Strong Growth in Future to 2030

The copper tubes market is driven by growing demand in HVAC, plumbing, and industrial applications due to copper’s durability, thermal conductivity, and corrosion resistance. Leading companies such as Mueller Industries, Wieland Group, and KME Group are focusing on innovation and expanding production capacity to meet rising global infrastructure and energy efficiency needs.

The copper tubes market is projected to grow from USD 29.14 billion in 2025 to USD 42.62 billion by 2030, at a CAGR of 7.9% during the forecast period. The report includes information on market trends and development, copper tubes market growth drivers, emerging technologies, and the investment structure of the market. Several key factors drive the global demand for copper tubes. Among these are the expanding construction and infrastructure sectors, where copper is increasingly favored for plumbing, HVAC applications, and refrigeration due to its strength, corrosion resistance, and superior thermal conductivity. The shift towards sustainable building practices and energy-efficient systems further enhances demand, as copper’s recyclability and eco-friendly characteristics align with modern environmental standards. Additionally, advancements in copper tube manufacturing technologies, particularly those that enhance performance in high-pressure applications, are contributing to the growing market interest.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41085011

“By form, straight tube to be largest segment for copper tubes market during forecast period”

Straight tubes dominate the global copper tubes market due to their extensive application across various industries. They are integral components in HVAC systems, refrigeration, plumbing, and the automotive sector, facilitating the transport of gases and fluids. The demand for straight copper tubes is driven by their ease of installation, cost-effectiveness, and reliability over time. These tubes are preferred in systems requiring high thermal and electrical conductivity, corrosion resistance, and mechanical strength. Their adaptability, including the capability to be easily fabricated or bent to meet specific requirements, further enhances their appeal to users. Given the robust growth in construction and manufacturing sectors worldwide—particularly in residential, commercial, and industrial infrastructure development—the demand for straight copper tubes remains strong.

“By application, HVACR to be largest segment of copper tubes market during forecast period”

HVACR represents the largest segment in the global copper tubes market driven by several compelling factors. Copper is preferred for HVACR systems due to its exceptional thermal conductivity, corrosion resistance, and durability, making it ideal for heat exchange and fluid conveyance applications. Copper tubes are integral components in air conditioning units, refrigerators, and heating systems, where efficient heat transfer is critical to performance.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=41085011

Moreover, copper’s natural antimicrobial properties contribute to the cleanliness and healthiness of HVACR equipment, ultimately enhancing their long-term efficiency. The growing emphasis on energy-efficient systems, spurred by environmental considerations and regulatory pressures, further elevates the demand for copper tube applications in HVACR. Additionally, the expansion of construction activities, especially in the commercial and residential sectors, along with an increasing need for advanced heating and cooling solutions, continues to sustain high demand for copper tubes in HVACR systems.

Copper Tubes Companies

The copper tubes market report comprises key companies such as Mueller Industries (US), Wieland Group (Germany), Hailiang Group (China), KME Group SpA (Italy), LUVATA (Finland), Cerro Flow Products LLC (US), KOBE STEEL, LTD.(Japan), Cambridge-Lee Industries LLC (US), Shanghai Metal Corporation (China), and Quindao Hongtai Copper Tube Co., Ltd. (China).

KOBE STEEL, LTD. (Japan)Founded in 1905 and headquartered in Kobe, Japan, KOBE STEEL (Kobelco) operates through three main segments: Materials (including copper tubes), Machinery, and Electric Power. It has a global presence with 247 group companies across 23 countries. In 2023, Japan accounted for 67% of revenue, followed by other regions (26%) and China (7%).

Wieland Group (Germany)Wieland, established in 1820 and based in Ulm, Germany, is a major global producer of copper and copper-alloy products. With around 400,000 metric tons produced annually, the company focuses on sustainable solutions like its cuprolife brand. Its copper tube offerings serve industries including HVAC, automotive, and renewable energy. Wieland has over 30 sites worldwide, including facilities in Germany, the US, China, and France.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=41085011

KME Group S.p.A. (Italy)KME Group, with roots back to 1866 and headquartered in Italy, is a leading manufacturer of copper and copper-alloy products for construction, electronics, and transportation. It emphasizes sustainability through recycling and emission reduction. With operations in Europe, North America, and Asia, KME’s facilities are located in Germany, France, Italy, Spain, China, and the US.

LUVATA (Finland)Founded in 1910 and headquartered in Pori, Finland, LUVATA develops advanced copper-based products for sectors like HVACR, automotive, energy, and electronics. It offers specialty tubes and components through its Electrical Power, Welding, and Specialty Products segments. A part of Mitsubishi Materials since 2017, LUVATA has manufacturing sites across North America, Europe, and Asia.

Cerro Flow Products LLC (US)Cerro Flow, part of Marmon Holdings under Berkshire Hathaway, is a prominent US-based manufacturer of copper tubing and flow control products for plumbing, HVAC, and construction. Headquartered in Illinois, it operates facilities in Missouri and distributes through a broad North American network, with a strong “Made in the USA” brand identity.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/copper-tubes-market-41085011.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Copper Tubes Market Share, Comprehensive Analysis, Opportunity Assessment, Strong Growth in Future to 2030

AAV Vectors in Gene Therapy Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 250+ pipeline drugs in AAV Vectors in Gene Therapy pipeline landscape. It covers the AAV Vectors in Gene Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the AAV Vectors in Gene Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in AAV Vectors in Gene Therapy Research. Learn more about our innovative pipeline today! @ AAV Vectors in Gene Therapy Pipeline Outlook

Key Takeaways from the AAV Vectors in Gene Therapy Pipeline Report

In July 2025, Adverum Biotechnologies Inc. announced a Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56.
DelveInsight’s AAV Vectors in Gene Therapy pipeline report depicts a robust space with 180+ active players working to develop 250+ pipeline therapies for AAV Vectors in Gene Therapy treatment.
The leading AAV Vectors in Gene Therapy Companies such as GenSight Biologics, Ultragenyx Pharmaceutical, MeiraGTx, Nanoscope Therapeutics, REGENXBIO, Astellas Gene Therapy, GeneCradle Therapeutics, Asklepios BioPharmaceutical, MeiraGTx, 4D Molecular Therapeutics, Adverum Biotechnologies, Rocket Pharmaceuticals, Innostellar Biotherapeutics, Passage Bio, Aspa Therapeutics, Solid Biosciences, Lantu Biopharma, Ascidian Therapeutics, Decibel Therapeutics, Sio Gene Therapies and others.
Promising AAV Vectors in Gene Therapy Pipeline Therapies such as Valoctocogene Roxaparvovec, AAV – CNGB3, SB-525 (PF-07055480), AAV2/5-RPGR, BMN 307, GC301, rAAV-Olig001-ASPA, and others.

Stay ahead with the most recent pipeline outlook for Adeno-Associated Virus (AAV) Vectors in Gene Therapy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adeno-Associated Virus (AAV) Vectors in Gene Therapy Treatment Drugs

AAV Vectors in Gene Therapy Emerging Drugs Profile

DTX401: Ultragenyx Pharmaceutical

DTX401 is an investigational AAV8 gene therapy designed to deliver stable expression and activity of G6Pase-α under control of the native promoter. DTX401 is administered as a single intravenous infusion and has been shown in preclinical studies to improve G6Pase-α activity and reduce hepatic glycogen levels, a well-described biomarker of disease progression. In a Phase I/II clinical study, all nine patients showed a clinical response, with significant reductions in the need for cornstarch and improvements in glucose control and other metabolic parameters compared to baseline. The drug is currently being evaluated in Phase III clinical trial to treat patients with Glycogen storage disease type I.

SRP-9003: Sarepta Therapeutics

SRP-9003 is in development for the treatment of LGMD2E (also known as beta-sarcoglycanopathy and LGMDR4), a devastating monogenic neuromuscular disease caused by a lack of beta-sarcoglycan (beta-SG) proteins. SRP-9003 is a gene therapy construct that transduces skeletal and cardiac muscle, delivering a gene that codes for the full-length beta-SG protein, the absence of which is the sole cause of the progressive degeneration and a shortened lifespan characterized by the disease.

GNT-0003: Genethon

GNT-0003 combines normal copies of the UGT1A1 gene coding for the bilirubin metabolizing enzyme with an AAV vector. The gene therapy, administered intravenously, was designed by Genethon’s Immunology and Gene Therapy of Liver Diseases team, led by Dr. Giuseppe Ronzitti. GNT0003 is a genetically modified recombinant (r) viral vector composed of the AAV8 viral capsid carrying the UGT1A1 transgene which aims to correct the dysfunction of the mutated gene by achieving durable expression of a functional copy of the affected gene. The drug is currently in Phase II stage of development for the treatment of Crigler-Najjar syndrome.

RP-A501: Rocket Pharmaceuticals

RP-A501 is Rocket’s investigational gene therapy product for the treatment of Danon disease and the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies. Danon disease is caused by mutations in the LAMP2 gene. RP-A501 consists of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a full-length, wild-type version of the human LAMP2B transgene (AAV9.LAMP2B) which, when inserted into heart cells harboring mutations in the endogenous LAMP2 gene, has the potential to fully restore cardiac function at its root. RP-A501 represents a single dose treatment and is administered as an intravenous infusion. In preclinical and clinical studies, AAV9.LAMP2B has been shown to target cardiac cells (cardiomyocytes) and deliver the functional LAMP2B gene to heart tissue, which ultimately leads to improved cardiac structure and function in patients.

HG202: HuidaGene Therapeutics

HG202 is a novel CRISPR/Cas13 RNA-targeting therapy packaged in a single adeno-associated viral (AAV) vector independently-developed by HuidaGene’s proprietary HG-PRECISE platform to target and knockdown the expression of VEGF-A mRNA within the local retina. This HG202 therapy is designed to treat nAMD patients who have developed resistance to anti-VEGF treatment as well as patients who are responsive to current standard anti-VEGF therapies. HG202 efficiently inhibits choroidal neovascularization better than existing therapies such as Aflibercept antibodies in head-to-head preclinical comparison studies. HG202 is currently being evaluated in a Phase I trial for the treatment of neovascular Age-related Macular Degeneration (nAMD).

RTX 015: Ray Therapeutics

RTX 015, also known as RAY-001, is a gene therapy that utilizes an adeno-associated virus (AAV) vector. It is being developed by Ray Therapeutics specifically for the treatment of retinitis pigmentosa, a degenerative eye disease that leads to vision loss. The therapy employs optogenetics, which involves the introduction of a gene that encodes a light-sensitive protein into retinal cells, thereby enabling these cells to respond to light and potentially restore vision in individuals with damaged photoreceptors.

IVB102: InnoVec Biotherapeutics

IVB102 is a drug for the treatment of X-linked retinoschisis (XLRS) developed based on a new vector independently developed by Innovecon. Preclinical data showed that the visual electrophysiological signals of model animals treated with IVB102 can be restored to a level comparable to that of wild-type animals, with the potential of being ‘best in class’. The positive feedback received from the FDA on IVB102 proves the FDA’s recognition of IVB102 and also reflects the urgent need for drugs from regulators and patients. Innovecon is rapidly advancing the clinical research of IVB102. The drug is currently being evaluated in a Phase I trial for the treatment of XLRS.

ZM-01: Zhongmou Therapeutics

ZM-01 is a novel gene therapy developed by Zhongmou Therapeutics, specifically designed for treating retinitis pigmentosa (RP), a hereditary retinal disease that leads to progressive vision loss and can result in legal blindness. This therapy utilizes an adeno-associated virus (AAV) vector to deliver genetic material aimed at addressing the underlying causes of RP, regardless of the specific mutations involved.

The AAV Vectors in Gene Therapy Pipeline Report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of AAV Vectors in Gene Therapy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AAV Vectors in Gene Therapy Treatment.
AAV Vectors in Gene Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
AAV Vectors in Gene Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AAV Vectors in Gene Therapy market.

Learn more about AAV Vectors in Gene Therapy Drugs opportunities in our groundbreaking AAV Vectors in Gene Therapy research and development projects @ AAV Vectors in Gene Therapy Unmet Needs

AAV Vectors in Gene Therapy Companies

GenSight Biologics, Ultragenyx Pharmaceutical, MeiraGTx, Nanoscope Therapeutics, REGENXBIO, Astellas Gene Therapy, GeneCradle Therapeutics, Asklepios BioPharmaceutical, MeiraGTx, 4D Molecular Therapeutics, Adverum Biotechnologies, Rocket Pharmaceuticals, Innostellar Biotherapeutics, Passage Bio, Aspa Therapeutics, Solid Biosciences, Lantu Biopharma, Ascidian Therapeutics, Decibel Therapeutics, Sio Gene Therapies and others.

AAV Vectors in Gene Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

AAV Vectors in Gene Therapy Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Discover the latest advancements in AAV Vectors in Gene Therapy treatment by visiting our website. Stay informed about how we’re transforming the future of Genetic Disorder @ AAV Vectors in Gene Therapy Market Drivers and Barriers, and Future Perspectives

Scope of the AAV Vectors in Gene Therapy Pipeline Report

Coverage- Global
AAV Vectors in Gene Therapy Companies- GenSight Biologics, Ultragenyx Pharmaceutical, MeiraGTx, Nanoscope Therapeutics, REGENXBIO, Astellas Gene Therapy, GeneCradle Therapeutics, Asklepios BioPharmaceutical, MeiraGTx, 4D Molecular Therapeutics, Adverum Biotechnologies, Rocket Pharmaceuticals, Innostellar Biotherapeutics, Passage Bio, Aspa Therapeutics, Solid Biosciences, Lantu Biopharma, Ascidian Therapeutics, Decibel Therapeutics, Sio Gene Therapies and others.
AAV Vectors in Gene Therapy Pipeline Therapies- Valoctocogene Roxaparvovec, AAV-CNGB3, SB-525 (PF-07055480), AAV2/5-RPGR, BMN 307, GC301, rAAV-Olig001-ASPA, and others.
AAV Vectors in Gene Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
AAV Vectors in Gene Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of AAV Vectors in Gene Therapy Pipeline on our website @ AAV Vectors in Gene Therapy Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
AAV Vectors in Gene Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
AAV Vectors in Gene Therapy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
DTX401: Ultragenyx Pharmaceutical
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
GNT-0003: Genethon
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
HG202: HuidaGene Therapeutics
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
AAV Vectors in Gene Therapy – Collaborations Assessment- Licensing / Partnering / Funding
AAV Vectors in Gene Therapy – Unmet Needs
AAV Vectors in Gene Therapy – Market Drivers and Barriers
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AAV Vectors in Gene Therapy Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

New Book More Than Hope Offers a Guiding Light for Families of Young Children on the Autism Spectrum

Dr. Tanya Paparella’s compassionate new release provides real answers and real hope for early childhood development and autism intervention.

Los Angeles, CA – For parents facing the uncertainty that often follows an autism diagnosis, More Than Hope: For Young Children on the Autism Spectrum offers something truly powerful: clarity, empowerment, and a pathway forward. Written by renowned clinical psychologist and early autism expert Dr. Tanya Paparella, this deeply insightful book is now available on Amazon in digital and paperback formats.

Rather than leaning into fear or helplessness, More Than Hope focuses on practical, science-backed strategies to help young children build critical developmental skills during the earliest and most crucial years of their lives. Drawing on over two decades of clinical experience and research, Dr. Paparella outlines how parents and caregivers can support meaningful growth in areas like communication, social interaction, behavior, and play, without feeling overwhelmed by complex medical language or unrealistic expectations.

This book doesn’t just speak to parents, it walks with them. It acknowledges the weight of a diagnosis but shifts the focus toward what can be done, and how everyday routines can become moments of progress. With a clear, warm voice, Dr. Paparella encourages families to become active participants in their child’s journey, offering a framework that is hopeful, achievable, and grounded in real-world experience.

At the heart of the book is a simple but powerful message: there is always something you can do to support your child, and those efforts can make a lasting impact. The title, More Than Hope, reflects this vision going beyond waiting or wishing and stepping into intentional action with confidence.

Families and professionals alike are praising the book for its accessibility and heartfelt approach. Rather than offering a one-size-fits-all solution, Dr. Paparella provides a foundation that respects the individuality of each child while equipping readers with the tools and mindset needed to foster growth.

Dr. Paparella is not only a leading voice in autism research, she’s someone who has stood beside hundreds of families navigating these early and emotional stages. Her experience shines through in every page, making More Than Hope a trusted companion for anyone beginning their autism journey.

More Than Hope: For Young Children on the Autism Spectrum is now available for purchase on Amazon. It’s more than a book it’s a lifeline of understanding, compassion, and direction for parents who want to make the most of these early years.

To learn more or to purchase the book, visit Amazon here.

For interviews, speaking engagements, or additional media inquiries, please contact Sage Grey at sgrey@inkstartmedia.com.

Media Contact
Company Name: Ink Start Media
Contact Person: Sage Grey
Email: Send Email
Country: United States
Website: https://www.amazon.com/More-Young-Children-Autism-Spectrum-ebook/dp/B0F1ZH87GR/ref=sr_1_2?crid=2592PGXULPW3P&dib=eyJ2IjoiMSJ9.0N4jMKzv0NneVE_jhYcrdwGGOydkpfUQlACj8_Cj5pHGjHj071QN20LucGBJIEps.GsizL4xdlzU5EfvJsb4fFck8pky_mCl-XchnA9tAs_g&dib_tag=se&keywords=More+Than+Hope%3A+For+Young+Children+on+the+Autism+Spectrum&qid=1752490179&s=books&sprefix=more+than+hope+for+young+children+on+the+autism+spectrum%2Cstripbooks-intl-ship%2C495&sr=1-2

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Book More Than Hope Offers a Guiding Light for Families of Young Children on the Autism Spectrum

Kingly T and Claudette King Drop “Live to Love” – A Cross-Genre Anthem for Unity

Reggae Meets Blues Royalty in Powerful New Single About Hope and Healing

In a time when the world could really use some healing, reggae powerhouse Kingly T is joining forces with Claudette King, the daughter of the legendary B.B. King. Their uplifting new single is titled “Live to Love.” Scheduled for an official release on August 14, this moving collaboration feels poised to become a timeless song of peace, love, and resilience.

“Live to Love” is a heartfelt call for global unity, compassion, and spiritual awakening. The lyrics inspire with lines like, “live to love, there will be blessings from above, live to love, life will be better.” The song radiates a message that can transcend borders, cultures, and generations.

This is music with a message and a mission. It’s a reminder that despite the chaos around us, we must choose to live to love.

As the youngest daughter of blues royalty, Claudette King carries the torch of a powerful musical legacy. Her collaboration with Kingly T marks a rare and meaningful fusion of reggae and blues, two genres rooted in the expression of struggle, hope, and liberation.

“Live to Love” arrives at a critical cultural moment, offering a much-needed sonic embrace to a world fractured by division and violence. It’s a bold, beautiful reminder that unity is strength, and that love remains the most powerful force we possess.

What makes this collaboration especially unique is the merging of two distinct worlds where reggae meets rhythm and blues. Claudette King’s powerful vocals, both emotive and edgy, meld effortlessly with Kingly T’s signature island-inspired sound. The result is an authentic sonic gem that feels as revolutionary as it is comforting. It’s a blend that speaks to all people, regardless of their background or musical taste.

As an artist, Kingly T is a musical messenger, deeply committed to spreading light, awareness, and love through his craft. His sound is deeply rooted in consciousness, cultural pride, and the uplifting spirit of the genre’s pioneers. His ability to write, perform, and produce thought-provoking tracks has earned him a growing global fanbase, and “Live to Love” only amplifies his mission.

With a rapidly growing discography that includes fan favorites like “We Can Do It,” “What A Gwaan,” “Change Direction (Remix),” and “No No No,” Kingly T has been carving out a distinct space in global reggae. His music, distributed through The Orchard, continues to build momentum as it reaches wider audiences. Check out Kingly T’s music and discover his catalog on Spotify. Now, with “Live to Love,” he’s poised to make an even greater impact.

For Claudette King, this collaboration marks another milestone in her evolving career. Carrying forward her father’s legacy, she continues to redefine herself by taking bold steps into new genres. Her performance on this track is truly transformative. Check out Claudette King’s music to experience her unique blend of blues heritage and contemporary artistry.

This single is a milestone for both artists, and a gift to the global community. Music lovers, humanitarians, and fans of reggae and soul alike should get ready.

“Live to Love” will be available on all major streaming platforms starting August 14th, 2025.

Don’t miss this genre-bending, soul-reviving, and globally relevant anthem. This is the kind of music the world needs now.

Connect with Kingly T Via Social Media:

YouTube: https://www.youtube.com/user/KinglyTmusic

Facebook: https://www.facebook.com/kinglyt

Instagram: https://www.instagram.com/kinglytmusic/

ReverbNation: https://www.reverbnation.com/kinglyt

X (Twitter): https://x.com/KinglyT

TikTok: https://www.tiktok.com/@tituskinglytwhitt

Hear more from Claudette King at https://www.claudettebluesking.com/

Media Contact
Company Name: Titus N Whittle
Contact Person: Kingly T
Email: Send Email
Phone: 317-523-8705
Country: United States
Website: https://www.claudettebluesking.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Kingly T and Claudette King Drop “Live to Love” – A Cross-Genre Anthem for Unity

Booked AI Launches AI-Powered Automated Deals Engine for Travel Booking Platform

Melbourne-based travel technology company introduces intelligent system that automatically delivers personalized travel deals directly to users through platform messaging.

Booked AI, the AI-powered travel booking platform, today announced the launch of its AI Automated Deals Engine. The new technology automatically identifies and delivers personalized travel deals to users through direct platform messaging, eliminating the need for manual deal searching across flights, hotels, and travel services.

The AI Automated Deals Engine analyses real-time market data, individual user preferences, and booking patterns to generate customized travel offers. The system proactively sends deal notifications directly to users within the platform, ensuring they receive relevant opportunities based on their travel history and stated preferences.

The technology addresses a common challenge in travel booking where consumers spend significant time comparing prices across multiple platforms. By automating this process, the engine delivers targeted deals without requiring users to actively search for opportunities.

The AI Automated Deals Engine incorporates several key functionalities designed to enhance the user experience. The system continuously monitors pricing fluctuations across global travel markets, automatically adjusting recommendations based on supply and demand changes. It generates personalized travel offers by analysing user data including past bookings, search patterns, and specified preferences for destinations, dates, and budget ranges.

The engine integrates seamlessly with existing booking processes, automatically applying discovered discounts and promotional rates during the reservation process. Users receive deal notifications through the platform’s messaging system, with each offer tailored to their individual travel profile and requirements.

The technology employs machine learning algorithms that improve recommendation accuracy over time. As users interact with the platform and complete bookings, the system refines its understanding of individual preferences, leading to increasingly relevant deal suggestions.

The engine covers comprehensive travel categories including flights, accommodations, car rentals, and travel activities. This integrated approach allows users to access optimized pricing across all aspects of their travel planning through a single platform.

“The launch of our AI Automated Deals Engine represents a significant advancement in how travellers discover and access competitive pricing,” said Mennan Yelkenci, Founder and CEO of Booked AI. “Rather than forcing users to constantly monitor prices or search multiple sites, our system works continuously in the background, delivering relevant opportunities directly to them based on their specific needs and preferences.”

The AI Automated Deals Engine is immediately available to all users of the Booked AI platform. The company plans to expand the engine’s capabilities throughout 2025, with enhancements including deeper market integrations and additional personalization features.

The technology launch supports Booked AI’s strategy to differentiate its platform through intelligent automation rather than traditional comparison shopping approaches.

Booked AI serves both individual travelers and corporate clients through its platform. The AI Automated Deals Engine functions across all user segments, with enterprise customers receiving additional features for managing travel policies and approval workflows.

The system operates by continuously scanning pricing data from multiple travel suppliers and distributors. When the engine identifies deals that match user preferences and criteria, it generates personalized notifications that appear within the platform’s messaging interface.

Users maintain control over notification frequency and deal categories through platform settings. The system respects user preferences for communication timing and deal types, ensuring that recommendations align with individual requirements.

The AI Automated Deals Engine represents part of Booked AI’s broader technology development focused on applying artificial intelligence to travel booking challenges. The company continues to invest in machine learning capabilities that enhance user experience while reducing booking complexity.

For more information about the AI Automated Deals Engine and its availability on the Booked AI platform, visit www.booked.ai.

About Booked AI

Booked AI operates an AI-powered travel booking platform that combines LLM’s with user-friendly booking experiences. The company serves individual travellers and corporate clients, focusing on personalised recommendations and competitive pricing across flights, hotels, and travel services.

Media Contact
Company Name: Booked AI
Contact Person: Mennan Yelkenci
Email: Send Email
Phone: +61 436 815 589
Country: Australia
Website: https://www.booked.ai

Online Payroll Service from IBN Technologies Boosts Accuracy

“Online Payroll Service [USA]”

IBN Technologies online payroll services tailored to support remote, hybrid, and global workforce models. The solution integrates with existing HR and ERP systems, payroll processing, ensures multi-state compliance, and enhances accuracy. Designed for businesses across manufacturing, logistics, retail, and healthcare, the platform helps reduce costs and administrative load.

Miami, Florida, 17 July 2025 In a strategic move addressing growing workforce complexities, IBN Technologies has launched a robust suite of online payroll services designed to support scalable, compliant, and cost-effective payroll management. As businesses transition to remote, hybrid, and global employment models, IBN Technologies’ new online payroll solutions offer a streamlined approach to handling payroll in real time—eliminating bottlenecks, reducing manual errors, and enhancing transparency.

With more than 26 years of expertise in finance and accounting outsourcing, IBN Technologies brings precision and dependability to payroll operations in sectors such as manufacturing, retail, logistics, eCommerce, and healthcare. By outsourcing payroll functions like wage computation, tax filing, onboarding, and compliance tracking, the platform meets growing demands for accuracy and operational agility in payroll management. As the global employment landscape becomes increasingly intricate, IBN Technologies delivers a smarter, centralized framework to navigate multi-jurisdictional regulations and workflow bottlenecks—without expanding internal administrative teams.

Need Reliable Payroll Experts for Your U.S. Business?

Get a Free Consultation: https://www.ibntech.com/free-consultation-for-payroll-service/

Common Payroll Challenges Impacting Business Efficiency

Despite advancements in the workplace, payroll operations still face several recurring roadblocks:

Manual data entry increases the chance of human error and late disbursements

Regulatory changes in tax and labor laws are difficult to keep pace with

Traditional systems struggle to support remote and hybrid staffing models

Payroll data is at risk without comprehensive encryption and privacy protocols

HR and finance departments remain overwhelmed by repetitive tasks

IBN Technologies’ Online Payroll Services: Secure, Compliant, and Scalable

IBN Technologies delivers targeted online payroll services that directly tackle these concerns using a cloud-native, configurable platform that provides end-to-end support. Each partnership begins with a business-specific audit to align implementation with operational needs, workforce distribution, and compliance priorities.

Core capabilities include:

✅ Tailored setup based on factory pay arrangements

✅ Full-scale tax filings and regulatory alignment for production industries

✅ Live shift wage monitoring integrated with attendance systems

✅ On-schedule release of wages, bonuses, and overtime pay

✅ HR advisory for contract staffing and scheduling flexibility

✅ Unified data storage with compliance-ready record access

✅ Compensation analysis and labor reports for unionized environments

✅ State-specific payroll support covering multiple jurisdictions

✅ Collaboration with finance leaders for workforce expense forecasting

✅ Protected processing of sensitive payroll and employee information

With regulatory insight, IBN Technologies converts payroll from a transactional duty into a strategic performance enhancer.

Proven Payroll Outcomes in U.S. Industries Through Tailored Support

As payroll complexities grow in industries throughout the U.S. companies are turning to experienced providers to fortify operational consistency. With heightened expectations for precision, legal compliance, and staff satisfaction, delegating payroll functions has become a vital operational strategy.

Consistently accurate payroll processing and punctual payments help reinforce compliance, elevate team productivity, and build trust

Clients have documented savings of up to $59,000 annually by partnering with established firms like IBN Technologies—cutting down on internal inefficiencies and minimizing payroll mishaps

In today’s demanding regulatory climate, dependable payroll support is foundational. IBN Technologies’ professionals work hand-in-hand with clients to reduce disruptions, maintain data fidelity, and deliver error-free payroll results. Their flexible offerings are shaped around each organization’s workforce model and business goals, enabling long-term scalability and resilience.

For example, a national logistics firm managing weekly compensation cycles for a dispersed workforce adopted IBN Technologies’ custom payroll system. The deployment improved time capture accuracy, automated tax reporting, and streamlined direct deposits at multiple locations. The improvements led to stronger financial governance and more satisfied employees due to prompt and clearly itemized payments.

This success highlights how IBN Technologies’ encrypted digital platform and local regulatory fluency help businesses reclaim valuable time, reduce compliance pressure, and build reliable payroll continuity.

Strategic Benefits of Payroll Outsourcing for Today’s Enterprises

Companies working with IBN Technologies for payroll solutions experience measurable advantages:

Reduced Overhead: Slash payroll-related costs by up to 70%

Improved Precision: Automation reduces miscalculations and errors

Enhanced Regulation Readiness: Stay ahead of compliance developments

Adaptable Operations: Scale payroll functions based on organizational growth

Resource Reallocation: Allow HR and finance to focus on high-priority initiatives

This streamlined model delivers increased clarity, control, and efficiency—positioning IBN Technologies as a valuable resource for organizations seeking sustained performance and cost control.

A Scalable Payroll Future Enabled by IBN Technologies

As workforce models diversify and geographic reach expands, businesses require payroll ecosystems capable of adapting instantly. IBN Technologies meets that demand through its online payroll solutions, offering flexibility without sacrificing security or compliance alignment.

The company’s success stories span industries such as logistics, where weekly wage disbursements were transformed through improved timekeeping, tax automation, and optimized direct deposit scheduling—ultimately reducing processing time and strengthening employee morale.

With multilingual customer service, transparent pricing models, and 24/7 support, IBN Technologies delivers scalable, integration-friendly payroll services suitable for businesses of all sizes. Its platform supports organizations ranging from lean startups to multinational teams, maintaining accurate, timely, and secure payroll execution at every stage.

Related Service:    

1. Bookkeeping: https://www.ibntech.com/bookkeeping-services/

2. Tax Preparation: https://www.ibntech.com/us-uk-tax-preparation-services/  

About IBN Technologies                

IBN Technologies LLC, an outsourcing specialist with 26 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.                

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Online Payroll Service from IBN Technologies Boosts Accuracy